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TreatmentBackground:Atrialfibrillation (AF) is common in chronic heart failure (HF) patients and influences the choice and
effects of drug and device therapy. In this large real-world HF registry, we studied whether the presence of AF
affects the prescription of guideline-recommended HF therapy.
Methods:We analyzed 8253 patients with chronic HFwith reduced ejection fraction (HFrEF) from 34 Dutch out-
patient clinics included in the period between 2013 and 2016 treated according to the 2012 ESC guidelines.
Results: 2109 (25.6%) of these patients were in AF (mean age 76.8 ± 9.2 years, 65.0% were men) and 6.144
(74.4%) had no AF (mean age 70.7 ± 12.2 years, 63.6% were men). Patients with AF more often received beta-
blockers (81.7% vs. 79.7%, p = 0.04), MRAs (57.1% vs. 51.7%, p b 0.01), diuretics (89.7% vs. 80.6%, p b 0.01) and
digoxin (40.1% vs. 9.3%, p b 0.01) compared to patients without AF, whereas they less often receive renin-
angiotensin-system (RAS)-inhibitors (76.1% vs. 83.1%, p b 0.01). The number of patients who received beta-
blockers, RAS-inhibitor and MRA at ≥50% of the recommended target dose was comparable between those
with and without AF (16.6% vs. 15.2%, p = 0.07).
Conclusion: In this large cohort of chronic HFrEF patients, the prevalence of AF was high and we observed signif-
icant differences in prescription of both guideline-recommended HF between patients with and without AF.
© 2020 Elsevier B.V. All rights reserved.1. Introduction
Atrialfibrillation (AF) is a common comorbidity in chronic heart fail-
ure (HF) patients,with a prevalence that has been reported from10%up
to 50–60%, depending on age and severity of HF [1–3]. Pathophysiolog-
ical changes in HF can lead to AF and vice versa [2,4]. HF induces ele-
vated filling pressures in the atria, leading to interstitial fibrosis of the
left atrium, eventually leading to AF. Furthermore, calcium handling is
altered in HF patients, and due to alterations in the electric properties
of the atrial tissue in HF patients, AF can be induced. Otherwise, AFy, Erasmus University Medical
etherlands.
nner-La Rocca, G.C.M. Linssen
ional Journal of Cardiology, haffects the left ventricular function due to loss of atrial contraction, ir-
regular ventricular heart rhythm, and often rapid ventricular response,
leading to and sustaining HF.
Multiple studies have shown that incident AF in chronic HF patients
is associatedwith an increased risk of all-causemortality, cardiovascular
mortality, stroke and transient ischemic attack [1,5]. Moreover, con-
comitant AF may influence the choice of HF therapy, as the effects of
therapies may differ in HF patients with AF [6]. There are European So-
ciety of Cardiology (ESC) guidelines for both HF and AF, providing clear
recommendations for the treatment of both conditions [7,8]. Informa-
tion on the ESC HF guideline adherence in patients with and without
AF is relatively scarce.
Therefore, the aim of this studywas to (1) investigate the adherence
to the HF ESC guidelines in HF patients with reduced ejection fraction, et al., Atrial fibrillation in chronic heart failure patients with reduced
ttps://doi.org/10.1016/j.ijcard.2020.03.001
2 J.F. Veenis et al. / International Journal of Cardiology xxx (xxxx) xxx(HFrEF) depending on the existence of underlying AF as well as to
(2) provide insight in the prescription of antiarrhythmic drugs and
anticoagulation therapy in HFrEF patients with AF in a practice-based
registry.
2. Methods
The design andmethods of the CHECK-HF (Chronisch Hartfalen ESC-
richtlijn Cardiologische praktijk Kwaliteitsproject HartFalen) registry
have been reported in detail earlier [9]. Briefly, the CHECK-HF registry
consists of 10,910 patients with chronic HF from a total of 34 participat-
ing Dutch centers, participating in the inclusion of this cross-sectional
observational cohort. Between 2013 and 2016, all centers included pa-
tients diagnosed with HF-based on symptoms, signs, ECG, biomarkers
and echocardiography according to the 2012 ESC Guideline on HF
[10], whowere seen at the outpatient HF clinic (96%) or general cardiol-
ogy outpatient clinic (4%) if no specific HF clinic was present. No NT-
proBNP threshold levels were used as inclusion criteria in this registry.
The study was conducted according to the Declaration of Helsinki. Eth-
ical approval was provided for anonymously analyzing existing patient
data by the Ethical Committee of theMaastricht UniversityMedical Cen-
ter, the Netherlands.
A dedicated databasewas used to register all available records of the
included patients, includingbaseline characteristics, laboratorymarkers,
device implantation rates, aswell as prescription anddosages ofmedica-
tion. Furthermore, information on contraindications and drug intoler-
ance were collected. For HF medical therapy, sotalol was analyzed
separately from other beta-blockers. Target doses of guideline recom-
mended HF therapy are presented in Supplementary Table 1.
Patients were classified based on left ventricular ejection fraction
(LVEF) or visual assessment of the left ventricle (LV) function into
HFrEF (LVEF b50% (n = 8360 (76.6%)) and HF with preserved ejection
fraction (HFpEF) (LVEF≥50% (n = 2267 (20.8%) according to 2012 ESC
HF guidelines [10]. In 283 (2.6%) patients data on LV functionwas insuf-
ficient to classify patients, these patients, and all HFpEF patients, were
excluded from this analysis. Based on a 12‑lead ECG, performed during
the most recent out-patient clinic visit, HFrEF patients were divided
into those with documented AF (or a documented history of AF), sinus
rhythm or other cardiac rhythms, in 107 (1.3%) patients data on cardiac
rhythmwasmissing, and these patients were excluded from this analy-
sis. Thus, a total of 8253HFrEF patientswith AF orwithout AF (including
sinus, pacemaker, and ectopic rhythm) was included.
2.1. Statistical analysis
Continuous data are expressed as mean value ± standard deviation
(SD) or median and interquartile range, depending on the distribution
of the data, and compared by the unpaired t-test or Mann-Whitney U
test when appropriate. Categorical data are expressed as counts and
percentages, and compared by the Pearson Chi-square test. In order to
investigate whether the observed differences according to AF were in-
dependent of potential confounders, such as age and sex, univariable
and multivariable logistic regression were used. The results of these re-
gression analyses are expressed as odds ratios (ORs) and 95% confi-
dence intervals (CIs). A two-sided p-value of 0.05 was considered
statistically significant.
In model 1, we adjusted for heart rate (per 10 beats/min). In model
2, we further adjusted for age, sex, New York Heart Association (NYHA)
classification, and LVEF. In model 3, we further included all comorbidi-
ties which were significantly related to the outcome variable at statisti-
cal level p-value b0.05 using the enter method in a binary logistic
regression model.
For some of these potential confounders, data were missing and
were imputed using multiple imputation. If the missing variables
showed a monotone pattern of missing values, the monotone method
was used. Otherwise, an iterative Markov chain Monte Carlo methodPlease cite this article as: J.F. Veenis, H.-P. Brunner-La Rocca, G.C.M. Linssen
ejection fraction: The CHECK-HF r..., International Journal of Cardiology, hwas used with a number of 10 iterations. A total of 5 imputations
were performed, and the pooled data were analyzed. The imputed
data was only used for the multivariable analysis. For all reported data
of the multivariable analysis, we compared crude and imputed p-
values aswell as theORs andCIs in order to analyzewhether imputation
changed the results, and if no significant changes occurred,we only pre-
sented the imputed values in the main analyses.
A sensitivity analysis was conducted for patients with documented
AF (n = 2109) and documented sinus rhythm (n= 4901).
For a sub-analysis according to the newer 2016 ESC HF guidelines,
patients with an assessed LVEF b50% were categorized into HF with
mid-range ejection fraction (HFmrEF) (LVEF 40–49% (n = 1559
(18.9%)) and HFrEF (LVEFb40% (n = 5625 (68.2%), only in those pa-
tients with a exactly specified LVEF or into patients with only a semi-
quantitative analysis of the LV function (n = 1069 (13.0%)). For a sub-
analysis according to type of AF, patients diagnosed with AF were cate-
gorized into those with paroxysmal, persistent, permanent AF or AF of
unknown type. All analyses were performed with SPSS Statistical Pack-
age version 25.0 (SPSS Inc., Chicago, Illinois).
3. Results
3.1. Baseline characteristics
Of all HFrEF patients, 2109 (25.6%) patients had AF on the entry-ECG
at themost recent out-patient clinic visit or had a documented history of
AF, 4901 (59.4%) had sinus rhythm, 1141 (13.8%) hadpacemaker rhythm
and 102 (1.2) had an ectopic rhythm (in total 6144 (74.4%) had no AF).
The prevalence of AF increased in higher NYHA-classifications (NYHA I
18.0%, NYHA II 24.8%, NYHA III 31.2% and NYHA IV 30.8%, p b 0.01). Pa-
tients with AF were significantly older compared to patients without
AF (76.8 ± 9.2 vs. 70.7 ± 12.2 years resp., p b 0.01), were more often
in NYHA III/IV (33.4% vs. 25.2% resp., p b 0.01), and had more comorbid-
ities compared to patients without AF as shown in Table 1.
3.2. Pharmacological therapy
Patients with AF significantly more often received beta-blockers
(81.7% vs. 79.7%, p = 0.04), mineralocorticoid receptor antagonists
(MRAs) (57.1% vs. 51.7%, p b 0.01), diuretics (89.7% vs. 80.6%,
p b 0.01), digoxin (40.1% vs. 9.3%, p b 0.01), oral anticoagulation
(OACs) (82.4% vs. 41.7%, p b 0.01) andnon-vitaminK antagonist oral an-
ticoagulant (NOACs) (7.3% vs. 3.6%, p b 0.01), and less often RAS-
inhibitors (76.1% vs. 83.1%, p b 0.01), amiodarone (12.9% vs. 15.2%,
p = 0.04), and sotalol (2.7% vs. 5.6%, p b 0.01) compared to patients
without AF, as shown in Fig. 1A. 89.7% of the patients with AF receive
(N)OAC therapy as compared to 45.4% of those without AF (p b 0.01).
Reasons for prescription of anticoagulation in patients without AF
were artificial valves, severe LV dysfunction or LV thrombus. As shown
in Fig. 1C, therewere no significant differences in the number of patients
who received tripleHF therapy, consisting of beta-blocker, RAS-inhibitor,
and MRA. Additionally, patients with sinus rhythm had more often an
implantable cardioverter defibrillator (29.0% vs. 15.4%, p b 0.01) or a car-
diac resynchronization therapy device (9.9% vs. 7.3, p b 0.01) compared
to patients with AF.
The prescribed dosages of beta-blocker, RAS-inhibitors, andMRA are
presented in Fig. 1B. Patients with AF significantly more often received
beta-blocker at target dose as compared to patients without AF, and
there were no significant differences in the prescribed dosages of RAS-
inhibitors and MRAs. As shown in Fig. 1D, there was no significant dif-
ference in the number of patients who received triple HF therapy at
≥50% at the target dose.
A sensitivity analysis excluding patients with pacemaker rhythm
and ectopic rhythm produced qualitatively similar results with the ex-
ception of beta-blockers, which difference was no longer significant
(Supplementary Fig. 1)., et al., Atrial fibrillation in chronic heart failure patients with reduced
ttps://doi.org/10.1016/j.ijcard.2020.03.001
Table 1
Patient characteristics of HFrEF patients according to AF.
Overall population (n = 8253) Patients with AF (n = 2109) Patients without AF (n = 6144) p-Value
Age (years) (n = 8244) 72.3 ± 11.8 76.8 ± 9.2 70.7 ± 12.2 b0.01
Male gender (n = 8216) 5258 (64.0) 1366 (65.0) 3892 (63.6) 0.25
BMI, kg/m2 (n = 7599) 27.2 ± 5.2 27.1 ± 5.1 27.2 ± 5.2 0.48
NYHA (n = 8160)
I 1291 (15.8) 232 (11.1) 1059 (17.4)
b0.01
II 4644 (56.9) 1154 (55.5) 3490 (57.4)
III 2079 (25.5) 648 (31.2) 1431 (23.5)
IV 146 (1.8) 45 (2.2) 101 (1.7)
LVEF, % (n = 6097) 32.7 ± 10.6 35.3 ± 10.9 31.8 ± 10.3 b0.01
Cause of HF (n = 7998)
Ischemic cause of HF 4122 (51.5) 850 (41.6) 3272 (54.9)
b0.01Non-ischemic cause of HF 3876 (48.5) 1192 (58.4) 2684 (45.1)
Systolic BP, mmHg (n = 8159) 125.7 ± 20.7 124.4 ± 20.2 126.1 ± 20.8 b0.01
Diastolic BP, mmHg (n = 8164) 71.2 ± 11.4 71.6 ± 12.0 71.0 ± 11.1 0.04
Heart rate, bpm (n = 8199) 72.0 ± 13.9 77.0 ± 16.7 70.3 ± 12.3 b0.01
LBBB (n = 8253) 1411 (17.1) 324 (15.4) 1087 (17.7) 0.01
QRS ≥130 ms (n = 6899) 2757 (40.0) 549 (32.4) 2208 (42.4) b0.01
eGFR (n = 5813) 59.7 ± 24.6 57.6 ± 24.2 60.4 ± 24.7 b0.01
eGFR (n = 5813)
b30 655 (11.3) 180 (12.1) 475 (11.0)
b0.01
30–59 2410 (41.5) 671 (45.2) 1739 (40.2)
≥60 2748 (47.3) 632 (42.6) 2116 (48.9)
Comorbidity (n = 7399)
Hypertension 2949 (39.9) 843 (44.3) 2106 (38.3) b0.01
Diabetes mellitus 2148 (29.0) 589 (31.0) 1559 (28.4) 0.03
COPD 1372 (18.5) 358 (18.8) 1014 (18.4) 0.72
OSAS 491 (6.6) 120 (6.3) 371 (6.7) 0.51
Thyroid disease 551 (7.4) 160 (8.4) 391 (7.1) 0.06
Renal insufficiencya 3901 (56.3) 1156 (63.3) 2745 (53.8) b0.01
No relevant comorbidity 840 (13.6) 158 (9.6) 682 (15.0) b0.01
Previous interventions (n = 6529)
PCI 1658 (25.4) 310 (18.6) 1348 (27.7) b0.01
CABG 1450 (22.2) 363 (21.8) 1087 (22.4) 0.63
Valve intervention 523 (8.0) 173 (10.4) 350 (7.2) b0.01
Cardiac rhythm
Sinus rhythm 4901 (59.4) – 4901 (79.8)
–
Ectopic rhythm 102 (1.2) – 102 (1.7)
Pacemaker rhythm 1141 (13.8) – 1141 (18.6)
Paroxysmal AF 305 (3.7) 305 (14.5) –
Persisted AF 370 (4.5) 370 (17.5) –
Permanent AF 1116 (13.5) 1116 (52.9) –
AF of unknown type 318 (3.9) 318 (15.1) –
AF, Atrial Fibrillation; BMI, Body Mass Index; NYHA, New York Heart Association classification; LVEF, Left Ventricular Ejection Fraction; HF, Heart Failure; BP, Blood Pressure; LBBB, Left-
Bundle Branch Block; eGFR, estimated Glomerular Filtration Rate; COPD, Chronic Obstructive Pulmonary Disease; OSAS, Obstructive Sleep Apnea Syndrome; PCI, Percutaneous Coronary
Intervention; CABG, Coronary Artery Bypass Graft.
a Defined as eGFR b60 mL/min or a history of renal failure.
3J.F. Veenis et al. / International Journal of Cardiology xxx (xxxx) xxxAs shown in Table 2, after adjusting for heart rate, patients with AF
had still higher odds of receiving beta-blockers, MRAs, diuretics, di-
goxin, OACs and NOACs, and lower odds of receiving RAS-inhibitors
and sotalol. After additional adjustment for other potential confounders,
patients with AF had higher odds of receiving beta-blockers, MRAs, di-
uretics, digoxin, OACs and NOACs and lower odds of receiving sotalol
compared to patients without AF. Multiple imputation did not change
the results.
3.3. Medical therapy in patients with HFmrEF according to 2016 ESC
guidelines
Medical therapy did not differ between patients with HF with mid-
range ejection fraction (HFmrEF) and HFrEF in this registry according
to the latest HF guidelines. Baseline parameters are shown in Supple-
mentary Table 2. A sub-analysis of only HFmrEF patients showed a sim-
ilarmedical therapy pattern between patientswith andwithout AF as in
HFrEF patients (Supplementary Fig. 2).
3.4. Baseline characteristics and medical therapy according AF type
Several significant differences in baseline characteristicwere observed
between the different AF type cohorts, as shown in SupplementaryPlease cite this article as: J.F. Veenis, H.-P. Brunner-La Rocca, G.C.M. Linssen
ejection fraction: The CHECK-HF r..., International Journal of Cardiology, hTable 3. Additionally, patients diagnosed with paroxysmal AF and HF re-
ceived less often HF medical therapy compared to the other AF types,
while sotalol and amiodarone were more often prescribed (Supplemen-
tary Table 3).
4. Discussion
In this large practice-based outpatient registry, one-quarter of
the HFrEF patients had documented AF. Patients with AF were signif-
icantly older and had more symptomatic HF. The differences in the
prescription rates of antiarrhythmic drugs, anticoagulation and
guideline-recommended HF therapy according to AF, could not be
fully explained by heart rate, age or other patient characteristics.
These results provide more insight into the clinical profile of HF pa-
tients with AF and the guideline adherence in these patients.
4.1. Pharmacological therapy
The efficacy of beta-blockers in chronic HF patients in sinus rhythm
has clearly been demonstrated [8], and is reflected in high prescription
rates in recent large HF registries [11–13], as well as in this registry.
However, the efficacy of beta-blockers in HF patients with AF remains
unclear. Several explanations for a different efficacy of beta-blockers, et al., Atrial fibrillation in chronic heart failure patients with reduced
ttps://doi.org/10.1016/j.ijcard.2020.03.001
Fig. 1. A Prescription rates of HF therapy, antiarrhythmic drugs and anticoagulation therapy, B prescribed dosages of HF therapy expressed as percentage of recommended target dose, C
combination of beta-blocker, RAS-inhibitor and MRA, D and combination of beta-blocker, RAS-inhibitor and MRA at least ≥50% of target dose prescribed, between patients with and
without atrial fibrillation.
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Table 2
Multivariable analysis: the likelihood of receiving HF therapy in patients with AF compared with patients without AF.
Univariable Multivariable
OR p-value Model 1 Model 2 Model 3
OR p-Value OR p-Value OR p-Value
Beta-blocker 1.14 [1.01–1.30] 0.04 1.18 [1.04–1.35] 0.01 1.34 [1.17–1.53] b0.01 1.34 [1.17–1.54] b0.01
RAS-inhibitor 0.65 [0.57–0.73] b0.01 0.72 [0.64–0.82] b0.01 0.93 [0.82–1.06] 0.28 0.92 [0.80–1.05] 0.19
MRA 1.25 [1.13–1.38] b0.01 1.28 [1.16–1.42] b0.01 1.40 [1.26–1.56] b0.01 1.41 [1.26–1.57] b0.01
Diuretics 2.09 [1.79–2.44] b0.01 2.00 [1.71–2.34] b0.01 1.61 [1.36–1.89] b0.01 1.63 [1.38–1.92] b0.01
Amiodarone 0.82 [0.68–0.99] 0.04 0.93 [0.77–1.13] 0.47 0.93 [0.76–1.13] 0.45 0.93 [0.76–1.14] 0.48
Sotalol 0.47 [0.36–0.63] b0.01 0.53 [0.39–0.70] b0.01 0.54 [0.40–0.73] b0.01 0.54 [0.40–0.72] b0.01
Digoxin 6.53 [5.77–7.38] b0.01 6.17 [5.44–7.00] b0.01 6.13 [5.37–6.99] b0.01 6.16 [5.40–7.03] b0.01
OAC 6.53 [5.75–7.41] b0.01 6.60 [5.80–7.51] b0.01 6.12 [5.36–6.98] b0.01 6.22 [5.45–7.11] b0.01
NOAC 2.10 [1.69–2.62] b0.01 2.09 [1.66–2.62] b0.01 2.28 [1.80–2.89] b0.01 2.26 [1.80–2.87] b0.01
Model 1 included heart rate (per 10 beats/min).
Model 2 included heart rate (per 10 beats/min), age, gender, NYHA classification, left ventricular ejection fraction.
Model 3 included heart rate (per 10 beats/min), age, gender, NYHA classification, left ventricular ejection fraction, hypertension, diabetes mellitus, COPD, OSAS, thyroid disease, renal in-
sufficiency (defined as eGFR b60 mL/min or a history of renal insufficiency), and atrial fibrillation.
AF, Atrial Fibrillation; RAS, Renin-Angiotensin System; MRA, Mineralocorticoid Receptor Antagonists.
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lationship between heart rate andmortality outcomes in HF patients re-
ported inconsistent results. Sub-analysis from randomized controlled
trials did not show an association between mortality and heart rate
[14], while observational cohorts did, although these cohorts are at
risk for selection bias [15]. A recent meta-analysis demonstrated that a
higher heart rate was not associated with a higher mortality rate in HF
patients having AF [16]. Furthermore, differences in structural or cellu-
lar function in patients with AF could lead to a difference in the efficacy
of beta-blockers in these patients [17]. A higher heart rate could com-
pensate for the loss of the atrial kick in AF patients, and thus reducing
the effect of beta-blockers [18]. Moreover, irregularity might be less
with a higher heart rate.
In a meta-analysis based on individual patient data of basically all
major randomized controlled trials, Rienstra et al. demonstrated that
the beta-blockers did not reduce the risk of mortality in HF patients
with AF, in contrast to HF patients with sinus rhythm [19]. However,
this analysis was published after 2016 and could, therefore, not influ-
ence the prescription pattern in CHECK-HF. Additional registries are
required to see if this individual patient data based meta-analysis influ-
enced the prescription pattern of beta-blockers in HFrEF patients with
AF. Multiple other meta-analyses have investigated this relationship
with mixed results [6,20]. Several important factors might contribute
to the observed differences. Importantly, studies demonstrating a
reduction in all-cause mortality in HF patients with AF using beta-
blockers were all cohort studies [6]. The risk of inclusion and prescrip-
tion bias limited the results of these studies. Furthermore, patients in-
cluded in the randomized controlled trials were on average more
symptomatic patients compared with patients included in the cohort
studies. It could be that these less symptomatic patients could tolerate
beta-blockers better, and in a higher dose, and therefore benefit more
from beta-blockers, although this clearly is not the case in patients with
sinus rhythm. In a non-randomized cohort study, a dose-dependent effect
of beta-blockers in HF patients with AF has been demonstrated, with the
largest reduction of events in patients up titrated to the recommended
dosage [21].
RAS-inhibitors are a cornerstone in chronic HF treatment [8], and
could be used to prevent the occurrence of newparoxysmal AF episodes
in HF patients [22,23]. As shown in our registry, the prescription rate of
RAS-inhibitors in both HF patients with and without AF was high, and
the observed difference between the groups was explained by signifi-
cant confounders.
Two studies have compared the efficacy of MRAs in chronic HF pa-
tients with andwithout AF, demonstrating similar effects in the preven-
tion of cardiovascular deaths and HF-related hospitalizations [24,25].
Moreover, MRAs reduced the risk of any future AF event in HF patients,
although this was only investigated in a post-hoc analysis [25]. WePlease cite this article as: J.F. Veenis, H.-P. Brunner-La Rocca, G.C.M. Linssen
ejection fraction: The CHECK-HF r..., International Journal of Cardiology, hfound that patients with AFmore often receiveMRAs, even after adjust-
ment for several significant confounders. However, prescription rates
were relatively low in both groups. Recent registries, investigating the
guideline adherence of MRA in chronic HF patients without AF, showed
similar prescription rates between 40 and 60% [13,26]. HF patients with
AF might be considered to be sicker and were more often symptomatic,
indicated by the higher prevalence of AF in more symptomatic HF
patients.4.2. Antiarrhythmic drugs
In chronic HF patients, rhythm control for AF has not been shown to
be superior over rate control [27], and adequate rate control prevented
unfavorable ventricular remodeling in HF patients [28]. Moreover, in
the ESC AF guidelines, it is recommended (Class IA indication) that
rate control should be the initial approach in elderly patients with
minor AF-related symptoms [7]. Additionally, the ESCHF guidelines rec-
ommend reserving rhythm control for HF patients with a reversible
cause of AF, or those who do not tolerate AF [8]. This could explain the
relatively low prescription rates of amiodarone and sotalol in our regis-
try. Sotalol is considered to be contraindicated in HFrEF, explaining
the low prescription rate. However, a substantial portion of HF pa-
tients without AF did receive amiodarone and sotalol. These drugs
might be prescribed due to ventricular tachycardia and premature
ventricular complexes in patients without AF. Unfortunately, we
cannot determine the prescription indication of these medications
from our data.
In low dosages, digoxin exerts mainly neurohormonal effects, which
could be beneficial primarily for reducing hospitalizations in chronic HF
patients without AF [29]. The effect of digoxin in HF patients without AF
has been investigated in only one randomized controlled trial [30], and
showed a neutral effect on mortality, but a beneficial effect on hospital-
izations. Since then, post-hoc analyses from observational cohorts dem-
onstrated higher mortality in HF patients without AF treated with
digoxin. However, these results are at great risk for prescription bias,
with sicker HF patients receiving more often digoxin. Additionally, the
use of digoxin in patients with AF without HF is controversial as well,
as a meta-analysis demonstrated an association between digoxin use
in AF patients and an increased risk of all-cause and cardiovascularmor-
tality [31]. However, these results are based on post-hoc analyses from
observational cohorts which are at great risk for prescription bias,
with sicker patientsmore likely to receive digoxin. Therefore, it remains
unclearwhether it is safe to use digoxin in patientswith both AF andHF.
The upcoming DECISION trial (NCT03783429), a multicenter random-
ized controlled trial, will provide more insight into the effect of digoxin
in HF patients with AF., et al., Atrial fibrillation in chronic heart failure patients with reduced
ttps://doi.org/10.1016/j.ijcard.2020.03.001
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The importance of adequate anticoagulation therapy, in order to pre-
vent stroke, systemic embolism but also excess of bleedings in HF
patients with AF, is well known [32]. However, the PINNACLE-AF regis-
try and the EuroHeart survey demonstrated that only approximately
60–70% of HFrEF patients received anticoagulation therapy [33,34]. In
contrast, the prescription rates in CHECK-HF were higher, which
might be explained by the close monitoring of the Dutch thrombosis
service, reducing the risk of potential bleedings. Recently, two meta-
analyses showed the efficacy and safety of NOACs in chronic HF patients
with AF [35,36]. The prescription rates of NOACs in our registry were
very low, reflecting the period of 2013 up to 2016, in which NOACs
were just introduced in Dutch clinical practice. We expect that the pre-
scription rates also in HF patients have risen significantly since then. In
contrast, the prescription rates of oral anticoagulation therapy were
very high in patients with AF.5. Limitations and strengths
This practice-based registry has some limitations that should be
noted. Due to the cross-sectional design of the registry, no follow-up
data on patient outcomes is available. Also, some data was missing in
our study, which could have caused some bias, althoughmultiple impu-
tation did not influence the results. Furthermore, patients were divided
based on a 12‑lead ECG, performed during the most recent out-patient
clinic visit, or a documented history of AF. The history of AF might
have been incomplete, and paroxysmal AF patients could have been
missed. Additionally, no details on the indication for OAC/NOAC or
anti-arrhythmic therapy, such as a history of ventricular arrhythmias,
was available. Furthermore, in the newer guidelines [8], HF categories
based on LVEF have been changes, our analysis was limited by a small
number of patients where LV function was semi-quantitatively ana-
lyzed with echocardiography, and some newer treatment strategies,
such as the uptake sacubitril/valsartan (substitution for ACE-i/ARB) or
NOACs were only in small numbers used in this time period. Still,
NOACs improbably influences the already high us of anticoagulation in
AF and the use of RAS-inhibitors was high in both patients with and
without AF. Therefore, it is unlikely that the conclusions from CHECK-
HF are influenced by the focus on the period between 2012 and 2016.
The major strengths of this study are the large sample size and the re-
flection of true clinical practice of the nationwide outpatient HF man-
agement, with detailed information on HF medication prescription
rate and prescribed dosages.6. Conclusion
In this national registry, consisting of 8253 chronic HFrEF patients, sig-
nificant differences exist in prescription rates of guideline-recommended
HF therapy between patients with and without AF. These results show
the need for a better understanding of the efficacy and adherence of
guideline-recommended HF therapy in patients with AF.Compliance with ethical standards
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